Caxton Associates LLP Pacira Bio Sciences, Inc. Transaction History
Caxton Associates LLP
- $3.94 Trillion
- Q2 2025
A detailed history of Caxton Associates LLP transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 47,507 shares of PCRX stock, worth $1.18 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
47,507
Previous 51,764
8.22%
Holding current value
$1.18 Million
Previous $1.29 Billion
11.73%
% of portfolio
0.03%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding PCRX
# of Institutions
257Shares Held
51.4MCall Options Held
289KPut Options Held
130K-
Black Rock Inc. New York, NY8.01MShares$199 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.41MShares$134 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.4MShares$59.5 Million0.08% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.25MShares$56 Million0.04% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.15MShares$53.4 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.14B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...